Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Liraglutide,Inapplicable
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Recipient : Biocon
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Biocon Limited Signs Commercialization Agreement with Juno Pharmaceuticals in Canada
Details : Under the terms of this agreement, Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market.
Product Name : Liraglutide-Generic
Product Type : Peptide
Upfront Cash : Undisclosed
June 10, 2023
Lead Product(s) : Liraglutide,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Recipient : Biocon
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Amoxicillin Trihydrate,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Amoxicillin oral suspension is one of the most commonly prescribed antibiotics for children for the treatment of particular bacterial infections. Amoxicillin represents the first product that Juno will successfully import to address drug shortages throug...
Product Name : Amoxicillin-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2023
Lead Product(s) : Amoxicillin Trihydrate,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eptifibatide,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 30, 2023
Lead Product(s) : Eptifibatide,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketamine Hydrochloride,Inapplicable
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ketamine is a rapid-acting general anesthetic and NMDA receptor antagonist used for induction of anesthesia diagnostic and surgical procedures typically in combination with a muscle relaxant.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 05, 2023
Lead Product(s) : Ketamine Hydrochloride,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epinephrine,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Signet
Deal Size : Undisclosed
Deal Type : Financing
Signet Healthcare Partners Completes Growth Equity Investment in Juno Pharmaceuticals Corp.
Details : Juno intends to use these proceeds to expand its complex and high-value generic and biosimilar portfolio including Adrenaline Aguettant. Signet will further enhance Juno’s already strong growth profile given their extensive experience in pharma, and sp...
Product Name : Adrenaline Aguettant-Generic
Product Type : Hormone
Upfront Cash : Undisclosed
February 24, 2022
Lead Product(s) : Epinephrine,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Signet
Deal Size : Undisclosed
Deal Type : Financing
Reset All
